Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
An early-phase trial suggests safety and improvements in vision after treatment with the CRISPR-based therapy EDIT-101, providing proof of concept for in vivo retinal gene editing.